4//SEC Filing
Aclaris Therapeutics, Inc. 4
Accession 0001209191-15-075193
$ACRSCIK 0001557746operating
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 1:22 PM ET
Size
13.2 KB
Accession
0001209191-15-075193
Insider Transaction Report
Form 4
Tullman Stephen A.
Director
Transactions
- Conversion
Series C Preferred Stock
2015-10-13−17,437→ 0 total(indirect: By Trust)→ Common Stock (5,054 underlying) - Conversion
Common Stock
2015-10-13+46,188→ 394,014 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2015-10-13−110,000→ 0 total(indirect: By Trust)→ Common Stock (31,884 underlying) - Conversion
Series B Preferred Stock
2015-10-13−31,913→ 0 total(indirect: By Trust)→ Common Stock (9,250 underlying)
Holdings
- 521,739(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
- [F2]Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
- [F3]These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which Mr. Tullman's spouse serves as the trustee.
- [F4]These shares are held by NeXeption, LLC, of which Mr. Tullman is the Manager.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001557746
Filing Metadata
- Form type
- 4
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 1:22 PM ET
- Size
- 13.2 KB